FDA granted Priority Review for atezolizumab (anti-PDL1; MPDL3280A) for the treatment of people with locally advanced or metastatic urothelial carcinoma who had disease progression during or following platinum-based chemotherapy in the metastatic setting, or whose disease worsened within 12 months of receiving platinum-based chemotherapy before or after surgery. “Atezolizumab was granted Priority Review designation based...
Two lawsuits filed within days of each other in the U.S. District Court for the Northern District of Illinois claimed that Tempus AI Inc., an AI-driven precision and genomic testing company, had violated the Illinois Genetic Information Privacy Act when it acquired Ambry Genetics and started to integrate its genetics data into its predictive models.
